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Clinical characteristics and real-life
diagnostic approaches in all Danish
children with hereditary angioedema
Anne Aabom1,2* , Klaus E. Andersen1,3, Christina Fagerberg4, Niels Fisker5, Marianne A. Jakobsen6
and Anette Bygum1,2
Abstract
Background: With a potentially early onset, hereditary angioedema (HAE) requires special knowledge also in infancy
and early childhood. In children from families with HAE, the diagnosis should be confirmed or refuted early, which can
be difficult. Studies of childhood HAE and the diagnostic approaches are limited. Our aim was to investigate the entire
Danish cohort of children with HAE and non-HAE children of HAE patients for diagnostic approaches and clinical
characteristics.
Results: We included 41 children: 22 with HAE and 19 non-HAE. Of the HAE children, 14 were symptomatic—median
age at onset was 4 [1–11] years. The first attack was peripheral in 8/14 children and abdominal in 6/14 children, i.e. no
one had their first attacks in the upper airways. Most children had less than one attack per month. All of the
symptomatic children had been treated with tranexamic acid and/or C1 inhibitor concentrate. Unlike in other
countries, androgens were not used in our pediatric cohort. Home therapy with C1 inhibitor concentrate was
established in 9 cases: 6 children were trained in self-administration and 3 children were treated by parents.
Of the children, 10 had been diagnosed by symptoms, including 3 without family history—median age of
diagnosis among these children was 5.35 [2–13.2] years. In 31 children, HAE was diagnosed or refuted before
symptoms by blood samples. In 23 of these children, complement values were investigated, and in 9 cases
genetic testing was added to the complement measurements. In 8 children recently investigated, genetic testing was
first choice. Cord blood was used for complement measurements in 9 children and for genetic testing in 4 children.
Results of complement measurements were equivocal in several cases, especially in the cord blood samples, and the
sensitivity of low complement C4 for the diagnosis of HAE was 75%.
Conclusions: We investigated clinical characteristics in all Danish children with HAE. The rate of home therapy was
high and androgens had been avoided. Complement values were often equivocal, especially in cord blood samples.
Consequently, we have changed diagnostic practice to early genetic testing in children where the family mutation is
known.
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Background
Hereditary angioedema (HAE) is a genetic disease char-
acterized by recurrent attacks of subcutaneous swellings
and abdominal pain. It is caused by either a deficiency
(HAE type I) or a reduced functional capacity (HAE type
II) of complement C1 inhibitor. The age of onset is vari-
able, but half the patients develop symptoms before the
age of 10 years [1, 2]. Life-threatening attacks may occur
in the upper airways, and death due to asphyxiation has
been reported in children as young as 2 weeks old [3].
The course of HAE is unpredictable, and it is important
to establish a diagnosis early, ideally before onset in cases
with a family history. The diagnosis is based on clinical
manifestations and/or family history combined with
laboratory findings [4].
Diagnosis based on biochemical measurements
Biochemical investigation comprises the complement
values total antigenic C1 inhibitor (C1INH), functional
capacity of C1 inhibitor (fC1INH), and complement C4
(C4). According to diagnostic algorithms, a family history
of angioedema should lead to complement measurement
[5, 6]. For early diagnosis of newborns from HAE families,
cord blood has been used [7]. There is consensus that low
complement values obtained on two separate occasions
(one after the age of 12 months) are required to diagnose
HAE in asymptomatic children [4–6, 8]. However, most
complement assays lack validated reference values for
children. Furthermore, results may be equivocal despite
repeated measurements and must be interpreted with
caution.
Diagnosis based on genetic investigation
Alternatively to complement measurements, mutational
screening of the gene encoding C1INH can be used [9].
HAE is caused by mutations in the SERPING1 gene
(OMIM #606860) located on chromosome 11. The in-
heritance pattern is autosomal dominant, but 25% of
cases are de novo mutations [10]. If the family mutation
is known, children can be diagnosed early with genetic
testing performed on peripheral blood or blood from the
umbilical cord. Until now, this has not been recom-
mended as first choice [11].
With a potentially early onset, HAE requires special
knowledge in both diagnosis and overall management, also
in infancy and early childhood. However, original studies of
the special aspects of childhood HAE, including the diag-
nostic challenges, are limited. The aim of this study was to
describe clinical features of childhood HAE and evaluate
the real-life diagnostic approaches in Danish HAE families.
Methods
This retrospective study was undertaken at the Danish
HAE Comprehensive Care Centre, Odense University
Hospital in October 2016. Data collection began in January
2013 and children born after 1995 were included. Children
were identified via a nationwide HAE registry containing
data of all known Danish HAE families [12]. The search
had two steps: 1) All children in the registry with a diagno-
sis of HAE type I or II were identified. For convenience,
both symptomatic children and carriers of HAE who had
not yet experienced any attacks were all labeled HAE pa-
tients. In cases with a family history of HAE, all healthy
siblings were included (information about these children
was retrieved from medical records of the siblings with
HAE or the parents). Half-siblings were also included if
they shared the parent with HAE. 2) Medical records of all
adult HAE patients that were not parents of children
already included were searched for information about
other healthy children.
Clinical information from children with HAE (age at
onset, localization of attacks, attack frequency, and use
of therapy) was retrieved from the medical records. The
observation period for attack frequency and use of therapy
was 45 months (January 2013–October 2016). During this
observation period, children were excluded when they
turned 18 years old. Information on the diagnostic process
was retrieved from the medical records.
Results of complement measurements and genetic test-
ing were recorded in a research database. C1INH and C4
were measured with nephelometry, turbidimetry, or rocket
immunoelectrophoresis and fC1INH with chromogenic as-
says. Mostly, the analyses were performed by Unilabs,
Copenhagen, but in some cases they were performed by
other laboratories in Denmark or abroad. In each case, the
complement results were interpreted against the perform-
ing laboratories’ reference range for healthy adults. On this
background, complement values were categorized as “nor-
mal” (values within or above adult normal range), “low”
(values below adult normal range), or “equivocal” (cases
with inconsistency, e.g. low C1INH combined with normal
C4). Genetic testing for mutations in the SERPING1 gene
were performed with Sanger sequencing or Multiplex
Ligation-dependent Probe Amplification (MLPA) analysis.
Parental written consent to investigate the medical records
and to contact previous healthcare professionals was
granted, and the study was approved by the Danish Data
Protection Agency (14/38996).
Results
In 18 of 35 Danish HAE families, we identified 41
children (27 boys, 14 girls) eligible for the study; all
agreed to participate. Of these children, 22 had HAE (3
had type II) and 19 had not (named non-HAE). Among
the 19 non-HAE children, all had a parent with HAE
and 10 also had a sibling with HAE. Among the 22 chil-
dren with HAE, 14 were symptomatic. Clinical charac-
teristics are outlined in Table 1.
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In the observation period, 4 children turned 18 years
old and were thereafter excluded from study. Median
age at onset was similar in girls and boys, but age at on-
set ranged more widely among girls (girls: 5 [1–11]
years, boys: 4 [3–5.4] years). There was no correlation
between age at onset and number of attacks within the
observation period (data not shown).
All of the symptomatic children had received treatment
(Table 2).
Home therapy with C1INH concentrate was estab-
lished in 9 cases. In 6 cases, the child was trained in
self-administration (at the age 10.4–16.4 years), and in 3
cases treatment was administered by parents (established
when children were 5.8–12.1 years old).
The results of all diagnostic blood samples for children in
the cohort are outlined in Tables 3 and 4. Mostly, C1INH
and C4 had been measured with nephelometry or turbid-
imetry, and fC1INH with chromogenic assays. In one case,
C1INH had been measured with rocket immunoelectro-
phoresis (HAE5). In a few medical records, “normal” com-
plement values were reported, but the exact laboratory data
could not be retrieved. These missing values were noted in
the study, but were not given any diagnostic weight.
The diagnostic approaches are summed in Fig. 1. Of
the children, 7 had symptoms before they were tested.
Of these 7 children, 3 had no family history; one had a
proven de novo mutation, and the parents of the other 2
were asymptomatic with normal C1INH values. Median
diagnostic delay in the children with sporadic HAE was
2.8 [2.2–4.8] years versus 1.0 [0.5–1.3] years in cases
with a family history. Another 3 children from HAE
families were diagnosed at symptom onset based on
older blood samples, e.g. their diagnosis was formally
established when they had their first attack. Median age
of diagnosis among all 7 children diagnosed by symp-
toms with a family history was 4.4 [2–6.3] years, and for
the 3 without family history 8.8 [6.8–13.2] years.
In 31 children, HAE was diagnosed or refuted prior to
any symptoms by laboratory testing at mean age 0.4
[0–18.1] years. In 23 of these children, complement values
were investigated. In most cases, two complement mea-
surements were performed with at least one occurring
after the age of 1 year, but in 7 children HAE was refuted
by only one normal complement measurement. Genetic
testing was added in 9 other children whose diagnostic
course was characterized by repeated complement mea-
surements with incomplete or equivocal results. In 8 chil-
dren recently investigated, genetic testing was the first
choice (at age 0–18.1 years). The mean age of diagnosis or
refutation of HAE for all 38 children born into HAE fam-
ilies was 1.5 [0–18.1] years.
Cord blood was used for complement measurements
in 9 children and for genetic testing in 4 children. Cord
blood complement values were low in 5 children with
HAE and equivocal in 4 children (2 with HAE and 2
non-HAE). Results were equivocal in 44% of the comple-
ment measurements performed on cord blood compared
with 20% (12/60) of the peripheral complement mea-
surements in the cohort.
Discussion
We investigated clinical features and real-life diagnostic
approaches in 41 children from Danish HAE families.
Table 1 Clinical characteristics in 14 symptomatic children with
hereditary angioedema
Age at onset (years) Median 4 [1–11]
Localization of first attack
Abdominal 6/14 (43%)
Peripheral 8/14 (57%)
Upper airway 0
Types of attacks ever
Abdominal 14/14 (100%)
Peripheral 11/14 (79%)
Upper airway 4/14 (29%)
Number of attacks within the
observation period (45 months)a
Median 13 [4–121]
Frequency of attacks within the
observation period (45 months)
None 1/14 (7%)
Rare (< one attack per month) 10/14 (72%)
Frequent (≥ one attack per month) 3/14 (21%)
aNot including 4 children who turned 18 years old in the observation period
Table 2 Use of treatment among 14 children with hereditary
angioedema
Ever In the observation period
(Jan. 2013–Oct. 2016)
Tranexamic
acid
On-demand
treatment
9/14 4/14
Short-term
prophylaxisa
4/14 1/14
Long-term
prophylaxisb
4/14 1/14
C1INH
concentrate
On-demand
treatment
12/14 12/14
Short-term
prophylaxisa
5/14 4/14
Long-term
prophylaxisc
1/14 1/14
Icatibant On-demand
treatmentc
1/14 1/14
aIndications for short-term prophylaxis were dental treatment, holiday, school
camp, birthday, and other family events
bLong-term prophylaxis with tranexamic acid was used in 4 children for
0.2–5.6 years between 2006 and 2013
cOff-label
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Table 3 Results of diagnostic blood samples in 22 children with HAE
ID
sex
Born Age at onset/
diagnosis
Cord blood samples
[reference values for adults]
Peripheral complement measurements
[reference values for adults]
Genetic testingb
HAE1
f
1995 5/6 y n.d. 6 y
fC1INH 34
[70–130]%
8.8 y
C1INH 0.15
[0.21–0.39]g/L
fC1INH 55
[70–130]%
C4 0.13
[0.1–0.4]g/L
11.6 y
C1INH 129
[210–345]mg/L
fC1INH 9.2
[17.2–27.4]U/ml
C4 120
[157–257]U/mg
11.6 y
c.437delT,
p.Leu124TrpfsTer2
HAE2
f
1995 5/6.3 y Complement
values reported
as normal (missing)
6.3 y
fC1INH 33
[70–130]%
9.5 y
C1INH 0.05
[0.21–0.39]g/L
fC1INH < 20
[70–130]%
C4 0.08
[0.1–0.4]g/L
n.d.
HAE3
m
1996 4/4 y n.d. 2 y
fC1INH 34
[70–130]%
6.8 y
C1INH 0.05
[0.21–0.39]g/L
fC1INH 122
[70–130]%
C4 0.07
[0.1–0.4]g/L
8.5 y
C1INH 0.06
[0.21–0.39]g/L
fC1INH 23
[70–130]%
n.d.
HAE4
f
1996 1/2 y n.d. 2 y
fC1INH 22
[70–130]%
9.7 y
C1INH 0.06
[0.21–0.39]g/L
fC1INH 39
[70–130]%
C4 0.07
[0.1–0.4]g/L
9.8 y
c.23dupT, X19
in signal peptide
HAE5a
f
1999 11/13.2 y n.d. 13.2 y
C1INH <25
[72–153]%
fC1INH 27
[70–130]%
C4 0.05
[0.16–0.38]g/L
13.5 y
C1INH 0.08
[0.21–0.39]g/L
fC1INH 46
[70–130]%
C4 < 0.06
[0.1–0.4]g/L
13.7 and 15.1 y
No SERPING1
mutation found
HAE6
m
2000 3/3 y n.d. 2.3 y
C1INH 0.09
[0.21–0.39]g/L
fC1INH 47
[70–130]%
C4 0.2
[0.49–1.66]g/L
n.d.
HAE7a
m
2000 4/8.8 y n.d. 8.8 y
C1INH 0.07
[0.21–0.39]g/L
fC1INH 32
[70–130]%
C4 0.07
[0.1–0.4] g/L
9.8 y
c.1030_1503del,
deletion of exons
7 and 8
HAE8a
f
2000 4/6.8 y n.d. 6.8 y
fC1INH 20
[70–130]%
C4 < 0.04
[0.1–0.4]g/L
6.9 y
C1INH 0.14
[0.21–0.39]g/L
fC1INH 21
[70–130]%
C4 < 0.04
[0.1–0.4]g/L
7.5 y
c.1381G > C,
p.Ala439Pro
HAE9
f
2001 10/1.6 y C1INH 0.07 g/L
[0.21–0.39]
fC1INH 32%
[70–130]
C4 0.15 g/L
[0.1–0.4]
1.6 y
C1INH 0.12
[0.21–0.39]g/L
C4 0.08
[0.1–0.4]g/L
2.8 y
fC1INH 49
[70–130]%
7.3 y
C1INH 0.13
[0.21–0.39]g/L
fC1INH 50
[70–130]%
C4 0.08
[0.1–0.4]g/L
n.d.
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Table 3 Results of diagnostic blood samples in 22 children with HAE (Continued)
HAE10
f
2004 4.2/4.7 y n.d. 4.7 y
C1INH 0.06
[0.21–0.39]g/L
fC1INH 32
[70–130]%
4.8 y
C1INH 61
[210–345]mg/L
fC1INH <2
[17.2–27.4]U/ml
C4 68
[157–257]mg/L
4.8 y
c.551_685del,
deletion of exon 4
HAE11
m
type II
2004 -/5.7 y n.d. 5 y
C1INH 0.44
[0.21–0.39]g/L
fC1INH 56
[70–130]%
C4 0.07
[0.1–0.4]g/L
5.7 y
C1INH 0.34
[0.21–0.39]g/L
fC1INH 37
[70–130]%
6.3 y
c.1397G > A,
p.Arg444His
HAE12
m
2006 4/4.4 y C1INH 0.05
[0.21–0.39]g/L
C4 0.08
[0.1–0.4]g/L
4.4 y
fC1INH 37
[70–130]%
C4 0.1
[0.1–0.4]g/L
4.5 y
c.1417G > A,
p.Val451Met
HAE13
m
2006 5.4/3.8 y fC1INH 32
[70–130]%
1.3 y
fC1INH 69
[70–130]%
C4 0.11
[0.1–0.4]g/L
2.6 y
C4 0.08
[0.1–0.4]g/L
3.8 y
c.668_669delA,
p.Gln201fsTer10
HAE14
m
2008 3.3/2.7 y C1INH <0.03
[0.21–0.39]g/L
fC1INH <20
[70–130]%
C4 0.05
[0.1–0.4]g/L
1.1 y
C1INH <0.25
[0.21–0.39]g/L
fC1INH 65
[70–130]%
C4 0.04
[0.1–0.4]g/L
2.7 y
c.1-22-2A > G,
splicing defect
HAE15
m
2009 -/5.3 y n.d. 2.4 y
C1INH 0.16
[0.21–0.39]g/L
fC1INH 65
[70–130]%
C4 0.2 [0.1–0.4]g/L
4.4 y
C1INH 0.07
[0.21–0.39]g/L
fC1INH 83
[70–130]%
C4 0.07
[0.1–0.4]g/L
5.3 y
c.1250-1G > A,
splicing defect
HAE16
m
2009 3.8/1 y C1INH <0.03
[0.21–0.39]g/L
C4 0.04
[0.1–0.4]g/L
1 y
C1INH 0.13
[0.21–0.39]g/L
fC1INH 52
[70–130]%
C4 0.11
[0.1–0.4]g/L
1.7 y
c.551_685del,
deletion of exon 4
HAE17
m
type II
2012 -/2.8 y n.d. 2.8 y
c.1396 C > T,
p.Arg444Cys
HAE18
m
2012 -/2.1 y n.d. 2.1 y
c.762_763delCA,
p.Asn232LysfsTer2
HAE19
m
2012 -/1.8 y fC1INH 20
[70–130]%
0.9 y
C1INH 0.10
[0.21–0.39]g/L
fC1INH 56
[70–130]%
C4 0.08
[0.1–0.4]g/L
1.8 y
c.1250-1G > A
HAE20
m
2013 -/0.5 y C1INH 0.08
[0.21–0.39]g/L
C4 0.14
[0.1–0.4]g/L
0.5 y
c.1-22-2A > C,
splicing defect
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Median age at onset was 4 [1–11] years, which is in
accordance with a recent Swedish pediatric HAE study
[13]. In the other few original studies dedicated to
pediatric HAE, age at onset was slightly higher: in a
Hungarian study median age at onset was 5 years [14],
and in two US studies it was 5.7 and 7 years, respectively
[15, 16]. Like Farkas et al., we found that the first attack
was most commonly peripheral, closely followed by
abdominal attacks (Table 1) [17]. No one had their first
attacks in the upper airways. All symptomatic children
had experienced abdominal attacks, whereas peripheral
and upper airway attacks had occurred in 79% and
29% of the children, respectively. Numbers are similar
to those previously reported [16]. Most children had
less than one attack per month, which differs from a
Hungarian study with 11 of 26 children having fre-
quent attacks [18]. In contrast to a large US study,
we found no correlation between age at onset and
disease severity (our surrogate measure for disease
severity was number of attacks) [19].
Most of the treated children had tried more than one
type of therapy, which emphasizes the need for a tailored
approach. Unlike other countries [16, 20, 21], androgens
were not used in our pediatric cohort. This is note-
worthy, because the use of androgens in children with
HAE and the potential adverse effects are continuously
debated [6, 22]. Home therapy with intravenous C1INH
concentrate was established in 9 (64%) of the symptom-
atic children. Conversely, only 2 of 111 children (1.8%)
administered intravenous therapy at home in a UK
study, and 28% of treated children were managed at
home in Hungary [14, 21]. In our cohort, the youngest
child having treatment administered by parents was
5 years old, and the youngest child trained in self-
administration was 10 years old. The rate of children
able to self-administer was 6 of 9 (67%), which is consid-
erably higher than previously reported [23].
In our cohort, 24% of the children were diagnosed by
symptoms and the diagnosis was confirmed by blood
testing. This is comparable to 21% in a previous study
that also includes children with sporadic HAE [17]. The
median diagnostic delay among children with sporadic
HAE in our study was 2.8 years compared with a
diagnostic delay of 6 years in children without family
history in a US study [16].
The mean age at which HAE was diagnosed or refuted
was 1.5 years among the 38 children born into HAE
families. This is considerably lower than studies includ-
ing adult patients [1, 19] and also other pediatric studies
[13, 15–17]. However, HAE was refuted by only one set
of normal complement values in 7 non-HAE children,
which must be considered insufficient. Thus, the most
recent consensus paper on pediatric HAE specifies that
asymptomatic children with a family history of HAE
should be considered to have HAE until the diagnosis is
ruled out by two complement measurements with at
least one of them performed after the age of 1 year [6].
Among children with a family history of HAE, 7 devel-
oped symptoms before the diagnosis was formally estab-
lished with two complement measurements. This is not
optimal, as milder HAE symptoms might be missed if
children do not have a certified diagnosis.
However, complement measurements do not always
give clear results. Complement values can show consid-
erable age-specific variations in children [7, 24–27], and
most complement assays do not have reference levels for
children. In our cohort, equivocal or incomplete comple-
ment results occurred in several cases. This differs from
a Spanish HAE study demonstrating a very good agree-
ment between complement values and genetic testing in
children [28]. However, only 9 children under the age of
1 year were included. In that study, only C4 was found
unreliable, because values were falsely low in 5 non-
HAE children. We found, however, 7 cases of C4 values
within adult normal range among children with HAE
(all without symptoms and untreated when blood sam-
ples were taken). As C4 was measured 28 times among
children with HAE in our cohort, the sensitivity of low
C4 for the diagnosis of HAE was 75% (21/28), which is
comparable to a 81% sensitivity previously found [29].
The use of cord blood samples in our cohort seems
worth exploring. Among the 9 cord blood complement
measurements performed, 4 had equivocal results. In
addition, there seemed to be practical challenges of
handling blood for the sensitive complement assays in a
delivery room as another 3 cord blood samples were
Table 3 Results of diagnostic blood samples in 22 children with HAE (Continued)
HAE21
f
type II
2015 -/0 y Genetic testing, mutation
found
0 y
c.1396 C > T,
p.Arg444Cys
HAE22
m
2016 -/0 y Genetic testing, mutation
found
0 y
c.762_763delCA,
p.Asn232LysfsTer2
Complement values were equivocal (bold font) or low compared with adult normal range
N.d. not determined. - asymptomatic
asporadic HAE (no family history)
bamino acid numbering based on the mature protein (Genbank accession number #NM_000062)
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Table 4 Results of diagnostic blood samples in 19 non-HAE children
ID
sex
Born Age when
HAE was refuted
Cord blood samples
[reference values for adults]
Peripheral complement measurements
[reference values for adults]
Genetic testing
Non1
m
1996 4.8 y n.d. 4.8 y
fC1INH 121 [70–130]%
n.d.
Non2
m
1997 1.5 y n.d. 1.5 y
C1INH 162 [80–140]units
fC1INH 168 [70–130]%
n.d.
Non3
m
1997 18.1 y n.d. 2.9 y
Reported as normal,
but missing
18.1 y
Family mutation ruled out
Non4
f
1997 14.9 y n.d. <14.6 y (exact age
unknown)
Reported as normal
(missing)
14.9 y
C1INH 0.33 [0.21–0.39]g/L
fC1INH 120 [70–130]%
C4 0.18 [0.1–0.4]g/L
n.d.
Non5
m
1999 15.7 y n.d. 0.1 y
fC1INH 81 [70–130]%
15.7 y
Family mutation ruled out
Non6
m
1999 16.1 y n.d 1 y
fC1INH 166 [70–130]%
16.1 y
Family mutation ruled out
Non7
f
1999 1.9 y n.d. 1.9 y
fC1INH 110 [70–130]%
n.d.
Non8
f
2000 6.4 y n.d. 6.4 y
C1INH 0.27 [0.21–0.39]g/L
fC1INH 106 [70–130]%
C4 0.2 [0.1–0.4]g/L
n.d.
Non9
m
2000 5.9 y n.d. 4.3 y
C1INH 0.34 [0.21–0.39]g/L
fC1INH 129 [70–130]%
C4 0.11 [0.1–0.4]g/L
5.9 y
C1INH 0.34 [0.21–0.39]g/L
fC1INH 135 [70–130]%
C4 0.19 [0.1–0.4]g/L
n.d.
Non10
m
2002 9.1 y n.d. 9.1 y
C1INH 0.32 [0.21–0.39]g/L
fC1INH 116 [70–130]%
C4 0.27 [0.1–0.4]g/L
n.d.
Non11
m
2003 3.2 y n.d. 1.5 y
C1INH 0.38 [0.21–0.39]g/L
fC1INH 117 [70–130]%
C4 0.13 [0.1–0.4]g/L
3.2 y
C1INH 0.32 [0.21–0.39] g/L
fC1INH 134 [70–130]%
C4 0.22 [0.1–0.4]g/L
n.d.
Non12
m
2008 1.3 y n.d. 1.3 y
C1INH 0.4 [0.21–0.39]g/L
fC1INH 174 [70–130]%
C4 0.33 [0.1–0.4]g/L
n.d.
Non13
m
2008 1 y Taken, but not analyzed 0.8 y
C1INH 0.41 [0.21–0.39]g/L
fC1INH 179 [70–130]%
C4 0.31 [0.1–0.4]g/L
1 y
C1INH 0.35 [0.21–0.39]g/L
fC1INH 143 [70–130]%
C4 0.39 [0.1–0.4] g/L
n.d.
Non14
m
2009 4.4 y n.d 2.4 y
C1INH 0.3 [0.21–0.39]g/L
fC1INH 130 [70–130]%
C4 0.26 [0.1–0.4]g/L
4.4 y
C1INH 0.26 [0.21–0.39]g/L
fC1INH 123 [70–130]%
C4 0.24 [0.1–0.4]g/L
5.3 y
Family mutation ruled out
Non15
f
2009 1 y C1INH 0.2 [0.21–0.39]g/L
C4 0.14 [0.1–0.4]g/L
1 y
C1INH 0.43 [0.21–0.39]g/L
fC1INH 168 [70–130]%
C4 0.21 [0.1–0.4]g/L
1 y
Family mutation ruled out
Non16
m
2010 0.3 y C1INH 0.17 [0.21–0.39]g/L
C4 0.16 [0.1–0.4]g/L
1.4 y
C1INH 0.57 [0.21–0.39]g/L
fC1INH 252 [70–130]%
C4 0.5 [0.1–0.4]g/L
0.3 y
Family mutation ruled out
Non17
m
2013 0 y Taken for complement
measurement, but mishandled.
Instead used for genetic testing.
0 y
Family mutation ruled out
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mishandled so useful results could not be obtained. To
our knowledge, these data form the largest material pub-
lished on cord blood samples in children from HAE
families. A previous study reported data from cord blood
in 2 children of HAE patients, of whom one developed
HAE [7]. The fluctuating nature of complement values
in cord blood has been of concern in international pa-
pers [11, 30]. Our findings support that concern and the
method is not used anymore at the Danish HAE Centre.
Overall, our results sustain the recommendation that
complement measurements performed before the age of
1 year should be interpreted with caution [6]
In our experience, some families find it difficult to wait
for their child’s HAE diagnosis to be confirmed or re-
futed by repeated complement measurements. Likewise,
physicians are challenged on establishing emergency
plans with pediatricians and emergency rooms while the
diagnosis is pending. Genetic testing can be helpful in
equivocal cases, but until now it has not been recom-
mended as first choice [11]. Moreover, mutations cannot
be identified in around five percent of the cases even in
clear-cut HAE families [9, 31]. In our cohort, several in-
fants were investigated early by genetic testing, which may
partly explain why age at diagnosis was lower in this study.
Genetic testing also provided a final answer in some chal-
lenging cases and as a consequence it has been our first
choice in the most recent cases. It is less sensitive to sam-
ple handling compared with complement measurements,
and with a known family mutation the genetic analysis has
100% sensitivity and specificity. Also the expense of gen-
etic testing is decreasing. Complement assays are less
expensive, but it takes at least two measurements to con-
firm the diagnosis. Furthermore, there are costs related to
having a child under observation for HAE, e.g. supply of
emergency medicine. Also the psychological burden of an
unresolved case is an important issue.
Table 4 Results of diagnostic blood samples in 19 non-HAE children (Continued)
Non18
f
2014 0 y n.d. <0 y
Chorionic villous sampling.
Family mutation ruled out
Non19
f
2015 0 y Genetic testing, family mutation
ruled out
0 y
Family mutation ruled out
Complement values were equivocal (bold font) or normal compared with adult normal range
N.d. not determined
Fig. 1 The diagnostic approaches in 41 children investigated for hereditary angioedema
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Conclusions
We have investigated clinical characteristics of all Danish
children with HAE. The age at onset was slightly lower
than in other studies, but the distribution of the first at-
tacks was similar to other cohorts. Like in other studies,
abdominal and peripheral attacks were the most common
and upper airway attacks relatively rare. The rate of home
therapy was high and androgens had been avoided.
As the first, we have thoroughly investigated the diag-
nostic approaches in all children from an entire national
HAE cohort, and we present the largest material pub-
lished on cord blood samples in children from HAE
families. Complement values were often equivocal, espe-
cially in cord blood samples, and the sensitivity of low
C4 for the diagnosis of HAE was only 75%. Conse-
quently, we have changed diagnostic practice and do not
use cord blood for complement measurements anymore.
Instead, we will advocate for early postnatal genetic test-
ing in children where the family mutation is known.
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